Ethnic Diversity of DPD Activity and the DPYD Gene: Review of the Literature

Citations Over TimeTop 10% of 2021 papers

Abstract

Pharmacogenomic screening can identify patients with gene variants that predispose them to the development of severe toxicity from fluoropyrimidine (FP) chemotherapy. Deficiency of the critical metabolic enzyme dihydropyrimidine dehydrogenase (DPD) leads to excessive toxicity on exposure to fluoropyrimidine chemotherapy. This can result in hospitalisation, intensive care admissions and even death. Upfront screening of the gene that encodes for DPD (DPYD) has recently been implemented in regions throughout Europe and the United Kingdom. Current screening evaluates DPYD variants that are well described within Caucasian patient populations and provides genotyped-guided dose adjustment recommendations based upon the presence of these variants. This article reviews the differences in DPYD gene variants within non-Caucasian populations compared to Caucasian populations, with regard to the implications for clinical tolerance of fluoropyrimidine chemotherapies and genotype guided dose adjustment guidelines.

Related Papers

• → Translating DPYD Genotype into DPD Phenotype: Using the DPYD Gene Activity Score(2015)107 cited
• → Implications of Dihydropyrimidine Dehydrogenase on 5-Fluorouracil Pharmacogenetics and Pharmacogenomics(2002)122 cited
• → Germline pharmacogenomics of DPYD*9A (c.85T>C) variant in patients with gastrointestinal malignancies treated with fluoropyrimidines(2018)25 cited
• → Pharmacogenetics in Oncology: A Promising Field(2009)24 cited
• → Dihydropyrimidine dehydrogenase pharmacogenetics in the Taiwanese population(2004)34 cited